@article{491eebcfecd34b439153ec287a5aee27,
title = "XProtective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys",
abstract = "The global diversity of HIV-1 represents a critical challenge facing HIV-1 vaccine development. HIV-1 mosaic antigens are bioinformatically optimized immunogens designed for improved coverage of HIV-1 diversity. However, the protective efficacy of such global HIV-1 vaccine antigens has not previously been evaluated. Here, we demonstrate the capacity of bivalent HIV-1 mosaic antigens to protect rhesus monkeys against acquisition of infection following heterologous challenges with the difficult-to-neutralize simian-human immunodeficiency virus SHIV-SF162P3. Adenovirus/poxvirus and adenovirus/adenovirus vector-based vaccines expressing HIV-1 mosaic Env, Gag, and Pol afforded a significant reduction in the per-exposure acquisition risk following repetitive, intrarectal SHIV-SF162P3 challenges. Protection against acquisition of infection correlated with vaccine-elicited binding, neutralizing, and functional nonneutralizing antibodies, suggesting that the coordinated activity of multiple antibody functions may contribute to protection against difficult-to-neutralize viruses. These data demonstrate the protective efficacy of HIV-1 mosaic antigens and suggest a potential strategy for the development of a global HIV-1 vaccine. PaperClip",
author = "Barouch, \{Dan H.\} and Stephenson, \{Kathryn E.\} and Borducchi, \{Erica N.\} and Kaitlin Smith and Kelly Stanley and McNally, \{Anna G.\} and Jinyan Liu and Peter Abbink and Maxfield, \{Lori F.\} and Seaman, \{Michael S.\} and Dugast, \{Anne Sophie\} and Galit Alter and Melissa Ferguson and Wenjun Li and Earl, \{Patricia L.\} and Bernard Moss and Giorgi, \{Elena E.\} and Szinger, \{James J.\} and Eller, \{Leigh Anne\} and Billings, \{Erik A.\} and Mangala Rao and Sodsai Tovanabutra and Eric Sanders-Buell and Mo Weijtens and Pau, \{Maria G.\} and Hanneke Schuitemaker and Robb, \{Merlin L.\} and Kim, \{Jerome H.\} and Korber, \{Bette T.\} and Michael, \{Nelson L.\}",
note = "Funding Information: We thank M. Pensiero, S. Blackmore, R. Bradsky, C. Cabral, A. Cheung, J. Goudsmit, R. Hamel, B. Hibl, S. Howell, M. Iampietro, K. Kelly, D. Lynch, M. Marovich, C. Miller, J. Nkolola, A. O{\textquoteright}Sullivan, L. Parenteau, J. Perry, W. Rinaldi, J. Sadoff, A. SanMiguel, N. Simmons, J. Smith, F. Stephens, D. van Manen, G. Westergaard, and L. Wyatt for generous advice, assistance, and reagents. The HIV-1 PTE peptides were obtained from the NIH AIDS Research and Reference Reagent Program. We acknowledge support from the U.S. Military Research and Material Command and the U.S. Military HIV Research Program (W81XWH-07-2-0067); the National Institutes of Health (AI052074, AI060354, AI078526, AI084794, AI095985, AI096040, and AI100645); the NIAID Division of Intramural Research; the Ragon Institute of MGH, MIT, and Harvard; and the Bill and Melinda Gates Foundation (OPP1033091 and OPP1040741). M.W., M.G.P., and H.S. are employees of Crucell. Beth Israel Deaconess Medical Center and Los Alamos National Laboratory are co-owners of an HIV-1 mosaic antigen patent that has been licensed to Crucell. The opinions in this manuscript are those of the authors and do not reflect the views of the U.S. Department of the Army or the Department of Defense. ",
year = "2013",
month = oct,
day = "24",
doi = "10.1016/j.cell.2013.09.061",
language = "English",
volume = "155",
pages = "531",
journal = "Cell",
issn = "0092-8674",
publisher = "Elsevier B.V.",
number = "3",
}